Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled date : 2021 - 07 - 19 save search
Navidea Biopharmaceuticals Announces First 110 Subjects Imaged in NAV3-35 Normative Database Phase 2b Study to Support Rheumatoid Arthritis Indications
Published: 2021-07-19 (Crawled : 22:00) - biospace.com/
NAVB | $0.035 50.69% 15K
|
Health Technology
|
| O: 0.0%
H: 3.33%
C: 0.0%
phase 2 biopharma rheumatoid arthritis phase 2b imaging
Prometheus Biosciences Announces Initiation of Global Phase 2 Clinical Trial of PRA023 in Moderate-to-Severe Ulcerative Colitis (UC)
Published: 2021-07-19 (Crawled : 18:00) - globenewswire.com
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: -2.21%
H: 3.55%
C: 3.17%
phase 2 trial ulcerative colitis
Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
Published: 2021-07-19 (Crawled : 14:00) - biospace.com/
VRTX | News | $394.265 0.2% 930K
|
Health Technology
|
| O: -0.06%
H: 1.04%
C: -1.44%
treatment phase 2 trial
Lyndra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Lyndra’s Weekly Risperidone (LYN-005) for the Treatment of Adults with Schizophrenia and Other Indications
Published: 2021-07-19 (Crawled : 13:00) - biospace.com/
AIG | $74.23 1.7% 0.0% 3.5M
|
Finance
|
| O: -5.62%
H: 0.62%
C: -1.25%
treatment fda phase 2 schizophrenia positive
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib
Published: 2021-07-19 (Crawled : 12:00) - biospace.com/
RDHL | $0.4519 7.39% 6.88% 330K
|
Health Technology
|
| O: 2.37%
H: 7.45%
C: 3.64%
covid phase 2 biopharma phase 2/3 opaganib covid-19
Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer’s Association International Conference 2021 (AAIC)
Published: 2021-07-19 (Crawled : 11:00) - athira.com
ATHA | $2.12 2.91% 2.83% 200K
|
Health Technology
|
| O: -7.12%
H: 9.29%
C: 7.56%
alzheimer phase 1 conference ath-1017 phase 2 phase 3 alzheimer’s alzheimer's
Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate
Published: 2021-07-19 (Crawled : 05:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.17%
H: 0.7%
C: 0.2%
disease phase 2 vaccine trial
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.305 226.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
INSG | $3.03 25.21% 330K
|
Electronic Technology
KNW 4 | $0.59 -0.71% 18.64% 27K
|
Manufacturing
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
ASNS | $0.828 21.75% 17.86% 18K
|
UONE | $2.36 19.8% 16.53% 75K
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.